15-Aug-22

InterCure Reports Record Breaking Second Quarter Financial Results

Record revenue of over $3 7 million i in the second quarter of 2022 Representing an annual run rate of $1 50 million Adjusted EBITDA ii for Q2 increased 90 % YoY to $ 9 million Net income of $6 million for the Q2 of 2022 compared to $2 million in Q2 of 2021 Tenth consecutive quarter of profitable
11-Aug-22

InterCure to Release its Q2 2022 Results and Hold a Conference Call

Conference call scheduled for Tuesday, August 16, 2022, at 8:30am ET NEW YORK and TORONTO and HERZLIYA, Israel, Aug. 11, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the “Company”) today announced that it plans to release financial
21-Jul-22

InterCure Reports Record Preliminary 2022 Second Quarter Revenue – More Than Double YoY and 9% QoQ Growth

Estimated r evenue reach es CAD$3 6 million 1 ( a record NIS 95 million ) Anticipates c ontinued increase s in EBITDA Revenue growth e xpected to continue in Q 3 and throughout 202 2 NEW YORK and TORONTO and HERZLIYA, Israel, July 21, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd .
21-Jun-22

InterCure and Cookies Launch Flagship Retail Location in Vienna, Austria

NEW YORK and TORONTO and HERZLIYA, Israel, June 21, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) ("InterCure" or the “Company”) announced today the successful opening of the first flagship Cookies store in Austria, located in the Neubau district of Vienna.  The
02-Jun-22

InterCure and Cookies Successfully Launch Flagship Pharmacy in Be'er Sheva, Israel

Cookies Be'er Sheva is the largest medical cannabis dedicated pharmacy in Israel NEW YORK and TORONTO and HERZLIYA, Israel, June 02, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) ("InterCure" or the “Company”) announced today the grand opening of its flagship
16-May-22

InterCure Begins 2022 with Record Breaking First Quarter Financial Results

Record revenue of $3 4 1 million in the first quarter of 2022 Adjusted EBITDA 2 increased almost 1 1 0% year-over-year to $8 million Net income of $ 6 million for the Q1 of 2022 compare d to $ 2 million in Q1 of 2021 Seventh consecutive quarter of positive cash flow from operations $9 1 million
16-May-22

InterCure to Release its Q1 2022 Results and Hold a Conference Call

Conference call scheduled for Tuesday, May 17, 2022, at 8:00am ET NEW YORK and TORONTO and HERZLIYA, Israel, May 16, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the “Company”) today announced that it plans to release financial
09-May-22

InterCure to Participate in Upcoming Investor Conferences in May 2022

NEW YORK, TORONTO, and HERZLIYA, Israel, May 09, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the “Company”) today announced that that Alex Rabinovitch, Chief Executive Officer and Amos Cohen, Chief Financial Officer, will
03-May-22

InterCure to Participate in A.G.P.’s Spring Consumer Cannabis Conference

NEW YORK and TORONTO and HERZLIYA, Israel, May 03, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the “Company”) today announced that Alexander Rabinovitch, CEO of InterCure, will participate in Alliance Global Partners Spring
06-Apr-22

InterCure Reports Record Breaking Q4 and 2021 Results – Exceeded Preliminary Results

Another record year with continued industry leading growth and profitability supported by focused strategy and execution Revenue growth expected to continue in the first quarter and throughout 2022 Strong balance sheet with $89 million cash supporting future profitable growth NEW YORK and TORONTO
Displaying 1 - 10 of 19